Cargando…
The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study
BACKGROUND: The risk of cardiovascular disease is tremendously high in dialysis patients. Dialysis patients treated with vitamin D analogs show decreased cardiovascular morbidity and mortality compared with untreated patients. We examined the influence of two common vitamin D analogs, alfacalcidol a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136403/ https://www.ncbi.nlm.nih.gov/pubmed/25112372 http://dx.doi.org/10.1186/1471-2369-15-130 |
_version_ | 1782330998051045376 |
---|---|
author | Hansen, Ditte Rasmussen, Knud Rasmussen, Lars M Bruunsgaard, Helle Brandi, Lisbet |
author_facet | Hansen, Ditte Rasmussen, Knud Rasmussen, Lars M Bruunsgaard, Helle Brandi, Lisbet |
author_sort | Hansen, Ditte |
collection | PubMed |
description | BACKGROUND: The risk of cardiovascular disease is tremendously high in dialysis patients. Dialysis patients treated with vitamin D analogs show decreased cardiovascular morbidity and mortality compared with untreated patients. We examined the influence of two common vitamin D analogs, alfacalcidol and paricalcitol, on important cardiovascular biomarkers in hemodialysis patients. Anti-inflammatory effects and the influence on regulators of vascular calcification as well as markers of heart failure were examined. METHODS: In 57 chronic hemodialysis patients enrolled in a randomized crossover trial comparing paricalcitol and alfacalcidol, we examined the changes in osteoprotegerin, fetuin-A, NT-proBNP, hs-Crp, IL-6 and TNF-α, during 16 weeks of treatment. RESULTS: NT-proBNP and osteoprotegerin increased comparably in the paricalcitol and alfacalcidol-treated groups. Fetuin-A increased significantly in the alfacalcidol-treated group compared with the paricalcitol-treated group (difference 32.84 μmol/l (95% C.I.; range 0.21–67.47)) during the first treatment period. No difference was found between the groups during the second treatment period, and IL-6, TNF-α and hs-Crp were unchanged in both treatment groups. CONCLUSIONS: Paricalcitol and alfacalcidol modulate regulators of vascular calcification. Alfacalcidol may increase the level of the calcification inhibitor fetuin-A. We did not find any anti-inflammatory effect or difference in changes of NT-proBNP. TRIAL REGISTRY: ClinicalTrials.gov NCT00469599 May 3 2007. |
format | Online Article Text |
id | pubmed-4136403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41364032014-08-19 The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study Hansen, Ditte Rasmussen, Knud Rasmussen, Lars M Bruunsgaard, Helle Brandi, Lisbet BMC Nephrol Research Article BACKGROUND: The risk of cardiovascular disease is tremendously high in dialysis patients. Dialysis patients treated with vitamin D analogs show decreased cardiovascular morbidity and mortality compared with untreated patients. We examined the influence of two common vitamin D analogs, alfacalcidol and paricalcitol, on important cardiovascular biomarkers in hemodialysis patients. Anti-inflammatory effects and the influence on regulators of vascular calcification as well as markers of heart failure were examined. METHODS: In 57 chronic hemodialysis patients enrolled in a randomized crossover trial comparing paricalcitol and alfacalcidol, we examined the changes in osteoprotegerin, fetuin-A, NT-proBNP, hs-Crp, IL-6 and TNF-α, during 16 weeks of treatment. RESULTS: NT-proBNP and osteoprotegerin increased comparably in the paricalcitol and alfacalcidol-treated groups. Fetuin-A increased significantly in the alfacalcidol-treated group compared with the paricalcitol-treated group (difference 32.84 μmol/l (95% C.I.; range 0.21–67.47)) during the first treatment period. No difference was found between the groups during the second treatment period, and IL-6, TNF-α and hs-Crp were unchanged in both treatment groups. CONCLUSIONS: Paricalcitol and alfacalcidol modulate regulators of vascular calcification. Alfacalcidol may increase the level of the calcification inhibitor fetuin-A. We did not find any anti-inflammatory effect or difference in changes of NT-proBNP. TRIAL REGISTRY: ClinicalTrials.gov NCT00469599 May 3 2007. BioMed Central 2014-08-12 /pmc/articles/PMC4136403/ /pubmed/25112372 http://dx.doi.org/10.1186/1471-2369-15-130 Text en Copyright © 2014 Hansen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hansen, Ditte Rasmussen, Knud Rasmussen, Lars M Bruunsgaard, Helle Brandi, Lisbet The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study |
title | The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study |
title_full | The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study |
title_fullStr | The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study |
title_full_unstemmed | The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study |
title_short | The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study |
title_sort | influence of vitamin d analogs on calcification modulators, n-terminal pro-b-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136403/ https://www.ncbi.nlm.nih.gov/pubmed/25112372 http://dx.doi.org/10.1186/1471-2369-15-130 |
work_keys_str_mv | AT hansenditte theinfluenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT rasmussenknud theinfluenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT rasmussenlarsm theinfluenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT bruunsgaardhelle theinfluenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT brandilisbet theinfluenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT hansenditte influenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT rasmussenknud influenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT rasmussenlarsm influenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT bruunsgaardhelle influenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy AT brandilisbet influenceofvitamindanalogsoncalcificationmodulatorsnterminalprobtypenatriureticpeptideandinflammatorymarkersinhemodialysispatientsarandomizedcrossoverstudy |